



29 January 2020

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

Dear Sir/Madam

**CLARIFICATION OF ANNOUNCEMENT - COMMERCIAL AGREEMENT EXECUTED WITH
TASMANIAN ALKALOIDS PTY LTD**

Further to the announcement made by Medlab Clinical Limited (ASX: MDC) on 29 January 2020, Medlab wishes to confirm that:

- The term of the agreement with Tasmanian Alkaloids Pty Ltd is 3 years.
- The agreement can be extended for an additional term of 3 years upon mutual agreement.
- There are no material conditions required prior commencement and thus the agreement is effective immediately

For and behalf of the Board.

Dr Sean Hall
Managing Director

ISSUED FOR:	MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co
FOR FURTHER	DR SEAN HALL, CEO, MEDLAB CLINICAL
INFORMATION:	TEL: +61 2 8203 9520, sean_hall@medlab.co

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.